Thursday, June 28, 2018

Stryker Combining Industry-Leading Performance With Peaking Sector Valuations

Whether or not Stryker (SYK) is the best-run med-tech company these days is a debatable subject, but there's far less debate that the company's recent financial performance has been exceptional. Couple that with industry valuations that are at their highest level in a long, long time, and that is a powerful mix for Stryker's share price performance.

Although I don't believe there was much, if any, substance to the rumors of Stryker approach Boston Scientific (BSX), further M&A is a near-certainty, and Stryker has shown that it can successfully integrate and build on the companies it buys. I am concerned that there's not much room for sector valuation to go much higher, but that's been a losing call for a while now and I wouldn't be all that eager to short Stryker at this point.

Read more here:
Stryker Combining Industry-Leading Performance With Peaking Sector Valuations

No comments: